Mérieux Equity Partners is a private equity firm founded in 2009 and based in Lyon, France, specializing in venture, growth, and leveraged buyout investments within the healthcare and nutrition sectors. The firm focuses on companies involved in biotechnology, pharmaceuticals, medtech, life sciences, and related services, aiming to support entrepreneurs and industrial firms with innovative products and services. Mérieux Equity Partners leverages its international network and expertise to enhance the growth potential of its portfolio companies. Currently, the firm manages over €600 million in assets under management and has recently introduced a new fund dedicated to growth and leveraged buyout investments.
DeepUll is a biotechnology company dedicated to developing an innovative diagnostic system for early-stage sepsis. The company's approach focuses on rapidly identifying pathogens and delivering antibiogram results within hours. By utilizing artificial intelligence, DeepUll is able to determine the infective agent and provide insights into antimicrobial susceptibility, which helps reduce unnecessary antibiotic use. This system not only enables quick detection of pathogens and antibiotic resistance without the need for prior cultivation but also allows healthcare providers to assess a patient's immunological and functional status. Consequently, DeepUll's technology empowers doctors to predict the onset and progression of sepsis, facilitating timely clinical interventions even before symptoms manifest.
Ceva Santé Animale
Private Equity Round in 2025
Ceva Santé Animale S.A. specializes in the research, development, production, and marketing of veterinary pharmaceuticals and vaccines for both companion and farm animals. The company provides a diverse range of products, including treatments for behavior, cardiology, nephrology, dermatology, locomotion, parasitology, and reproduction management for companion animals. For farm animals, Ceva offers anti-infective products, vaccines, and reproductive management solutions for cattle, sheep, goats, swine, and poultry. Additionally, the company has developed tools such as the Ceva Lung Program, a mobile application that helps manage lung health in livestock. Established in 1988 and headquartered in Libourne, France, Ceva operates pharmaceutical and research facilities in various countries, including Canada, Brazil, Italy, Hungary, the United States, Japan, Mexico, China, and Canada. The company is actively involved in global welfare initiatives, collaborating with local organizations to enhance animal health and welfare.
Curea medical
Acquisition in 2025
Curea medical treats wounds by providing wound dressings. They provide skin protection and hygiene in body folds and between the toes, as well as for patients and nursing pads. They provide management and soft debridement, management for sensitive skin, and management for malodorous wounds such as exuding wounds with fresh granulation tissue, sensitive skin surrounding the wound, and burns. They also offer plast silicone tape, seamless tubular bandages, and much more.
CorFlow
Series B in 2024
CorFlow Therapeutics is a medtech startup that develops proprietary technologies for diagnosis and treatment of microvascular obstructions in heart attack patients. The CorFlow technologies enable interventional cardiologists to diagnose and treat MVO in severe heart attack patients thereby potentially reducing the short- and long-term complication rates in these patients.
Prothea Technologies
Series A in 2024
Prothea Technologies is a private medical technology business to provide lung cancer biopsy and therapy in a single hospital visit.
Innosyn
Acquisition in 2024
Innosyn uses flow chemistry, bio- and chemocatalysis to produce chemicals product or enzymes along with optimization of plant processes.
Labquality
Acquisition in 2023
Labquality is a provider of quality controls and reference materials aimed at ensuring quality assurance in medical laboratories and point of care testing. The company offers a range of services, including certification, regulatory consulting, and traceable quality controls, as well as calibrator reference materials. These services are designed to enhance patient safety through independent quality assessments and support clients in navigating industry regulations, quality management, and obtaining marketing authorizations. By focusing on the healthcare sector, Labquality plays a crucial role in promoting high standards within medical technology industries.
Amyl Therapeutics
Series A in 2023
Amyl Therapeutics is a preclinical stage biotechnology company. Amyl Therapeutics uses a novel mechanism to bind to the amyloid fold of toxic protein aggregates of various types, including antibody light chain (AL) or transthyretin (TTR) aggregates, which accumulate in peripheral organs to cause systemic amyloidosis diseases, but also amyloid-β (Aβ), Tau, and α-synuclein aggregates, which accumulate in the brain to cause Alzheimer's and Parkinson's diseases.
Broken String Biosciences
Series A in 2023
Broken String Biosciences is focused on creating a sequencing platform that enhances the assessment of genome stability, aiming to facilitate the development of safer cell and gene therapies. The company integrates advanced sequencing techniques with bioinformatics and artificial intelligence, enabling healthcare professionals to utilize a data-driven approach for the safe introduction of innovative medicines. Through its novel tools, Broken String Biosciences seeks to unlock advancements in therapeutic options, contributing to the evolution of medical treatments.
TISSIUM
Series D in 2023
TISSIUM is a privately owned medical device company based in Paris, France, focused on developing and commercializing innovative biodegradable sealants and adhesives for surgical wound closure, particularly in minimally invasive procedures. The company's products are designed to be non-toxic, bind effectively to tissues, and provide on-demand wound closure in the body’s dynamic environments. TISSIUM's technology is rooted in advanced research and intellectual property from renowned experts at MIT and Brigham & Women’s Hospital. The company aims to address various unmet clinical needs through its proprietary portfolio of fully biosynthetic, biomorphic, and programmable polymers. Founded in 2013, TISSIUM is supported by prominent healthcare investors, emphasizing its commitment to advancing surgical techniques through its groundbreaking solutions.
Mablink Bioscience
Series A in 2022
Mablink Bioscience is a biotechnology company specialized in the development of a new class of cancer drugs, called Antibody Drug Conjugate (ADC).
AstriVax
Seed Round in 2022
AstriVax aims for initial clinical validation of the platform technology, to develop a broad vaccination pipeline.
Cairdac
Series A in 2022
Cairdac is a medtech startup focused on developing an innovative leadless pacing system that utilizes a self-sustaining power technology. The company has achieved a significant milestone by creating the first self-sustaining pacemaker with a lifespan exceeding 15 years, leveraging a proprietary piezoelectric energy harvester in conjunction with a miniaturized power management circuit. Their unique product, the ALPS, is an autonomous and endoscopically implanted leadless pacemaker designed to harness the heart's kinetic energy for power. By integrating disruptive technologies into traditional pacemaker designs, Cairdac aims to provide a cost-effective solution that addresses the evolving needs of patients and healthcare professionals while enhancing the overall quality of life for those requiring cardiac rhythm management.
SeqOne Genomics
Series A in 2022
Healthcare is undergoing a revolution, known as genomic medicine, that uses the patient’s genomic information to optimise treatment. This trend is accelerating thanks to the arrival of New Generation Sequencing (NGS) techniques that have reduced the cost of decoding genomic material while increasing the amount useful data obtained. However, NGS has had only limited impact on mainstream healthcare due to the difficulties in analyzing more and richer genomic data. SeqOne’s mission is to provide tools that enable the healthcare industry to analyse NGS genomic data better and more cost-effectively to provide universal access to genomic medicine.
Dental Monitoring
Private Equity Round in 2021
Dental Monitoring, founded in 2014 by Philippe Salah, has developed a remote dental monitoring platform that enhances the capabilities of dental professionals through AI-driven solutions. The company aims to improve practice efficiency and precision in patient care by enabling the creation of automated workflows, protocols, and messaging. Its patented hardware allows patients to submit high-quality intraoral images at any time, facilitating virtual monitoring across various treatment types. Since its inception, Dental Monitoring has grown significantly, expanding its international workforce to over 400 employees across Europe, the USA, Australia, Hong Kong, and Singapore. The company is dedicated to empowering dental practices with innovative technology that supports personalized treatment plans and effective communication with patients.
Amyl Therapeutics
Series A in 2021
Amyl Therapeutics is a preclinical stage biotechnology company. Amyl Therapeutics uses a novel mechanism to bind to the amyloid fold of toxic protein aggregates of various types, including antibody light chain (AL) or transthyretin (TTR) aggregates, which accumulate in peripheral organs to cause systemic amyloidosis diseases, but also amyloid-β (Aβ), Tau, and α-synuclein aggregates, which accumulate in the brain to cause Alzheimer's and Parkinson's diseases.
Swixx Biopharma
Venture Round in 2021
Swixx Biopharma fully represents biopharma companies in the CEE. It is designed to fully replace biopharma, OTC, and medical device multinationals’ subsidiaries or business units in those countries, or therapeutic areas of CEE, that the multinational chooses not to enter, or to exit. The company was founded in 2014 and is registered in Baar, Switzerland. It has 100%-owned affiliates in Albania, Bosnia & Herzegovina, Bulgaria, Croatia, Czech Republic, Estonia, Greece, Hungary, Kosovo, Latvia, Lithuania, North Macedonia, Montenegro, Poland, Romania, Russia, Serbia, Slovakia, and Slovenia.
AcuSurgical
Series A in 2021
AcuSurgical is a startup focused on advancing vitreo-retinal surgery through the development of a robotic surgical assistant. This innovative device is designed to enhance the precision and effectiveness of eye operations, particularly for treating retinal diseases like age-related macular degeneration. By providing surgeons with advanced tools to filter tremors and improve visualization during procedures, AcuSurgical aims to improve outcomes and increase the success rates of retinal surgeries.
Plantex
Acquisition in 2021
Plantex is a manufacturer specializing in plant extracts for various applications, including nutraceuticals, food, animal nutrition, and cosmetics. The company produces a range of standardized products such as dry, liquid, soft, glycolic, and hydro-glycerinated extracts derived from natural raw materials. By leveraging its expertise in plant knowledge and production, Plantex aims to fulfill client requirements for authenticity, efficiency, and innovation in formulations, solubilization, and compression.
keepMED
Series C in 2020
keepMED Ltd. is a company focused on developing and commercializing innovative solutions for the treatment of Obstructive Sleep Apnea (OSA), a condition marked by repeated episodes of upper airway obstruction during sleep. The company's primary product, keePAP, is a lightweight and unobtrusive wearable device that includes a nasal interface and a miniature battery-operated control unit. Founded in 2012 and based in Rishon Le Zion, Israel, keepMED aims to provide effective treatment options for individuals suffering from OSA.
TARA Biosystems
Series A in 2020
Tara Biosystems provides predictive, in vitro human cardiac tissue models for use in drug discovery, safety assessment and translational medicine. Tara Biosystems offers a high-fidelity solution that is based on human stem cell-derived cardiac tissue matured to physiologically relevant adult-like levels and provides direct measures of cardiac functionality, including contractile force. The company is dedicated to pioneering predictive cardiac tissue models that enable the faster, safer, and more reliable development of new medicines.
Ceva Santé Animale
Venture Round in 2020
Ceva Santé Animale S.A. specializes in the research, development, production, and marketing of veterinary pharmaceuticals and vaccines for both companion and farm animals. The company provides a diverse range of products, including treatments for behavior, cardiology, nephrology, dermatology, locomotion, parasitology, and reproduction management for companion animals. For farm animals, Ceva offers anti-infective products, vaccines, and reproductive management solutions for cattle, sheep, goats, swine, and poultry. Additionally, the company has developed tools such as the Ceva Lung Program, a mobile application that helps manage lung health in livestock. Established in 1988 and headquartered in Libourne, France, Ceva operates pharmaceutical and research facilities in various countries, including Canada, Brazil, Italy, Hungary, the United States, Japan, Mexico, China, and Canada. The company is actively involved in global welfare initiatives, collaborating with local organizations to enhance animal health and welfare.
addmedica
Private Equity Round in 2019
ADDMEDICA is a French medical product company focused on developing and marketing innovative and personalized solutions for patients with rare diseases and serious medical conditions. The company addresses significant unmet medical needs within niche markets by creating specialized medical products that can be used alongside or as alternatives to traditional drugs. ADDMEDICA's expertise allows it to target these unique medical products globally, ensuring they are accessible to health professionals and patients alike. The company's portfolio includes treatments for conditions such as sickle cell disease, emphasizing a commitment to delivering high medical value to physicians, patients, and managed care organizations.
Mabtech
Private Equity Round in 2019
Mabtech develop, manufacture, and market monoclonal antibodies and kits suited for ELISA, ELISpot and FluoroSpot.
Amphivena Therapeutics
Series C in 2019
Amphivena Therapeutics is a clinical-stage immuno-oncology company that develops a platform of dual-function biologics. Its Amphivena ReSTORE platform provides dual-action biologics that relieve immune suppression and activate T cell effector function in cancer patients. The platform design integrates elements of avidity, target selectivity, and enhanced safety within a single molecule. It is also can be engineered with additional solid tumor targeting modalities to add functionality such as directed tumor cell killing. It was founded in 2012 and is headquartered in South San Francisco, California.
Keranova
Venture Round in 2019
Keranova S.A., founded in 2015 and based in Saint Etienne, France, along with an office in Vénissieux, specializes in designing and developing innovative surgical equipment for ophthalmology, specifically targeting the anterior segment of the eye. The company focuses on creating advanced surgical instruments that aim to enhance existing semi-manual, operator-dependent procedures in ophthalmic surgery. Keranova's patented technology allows for a novel approach to anterior segment surgery, utilizing automated equipment equipped with vision, intelligent software, and precise robotic movements. This innovation significantly reduces the need for manual intervention, thereby improving the reproducibility and efficiency of surgical procedures.
Doc Generici
Private Equity Round in 2019
Doc Generici s.r.l. is an Italian company based in Milan that specializes in the production and distribution of generic medicines. Established in 1996 following the approval of legislation that facilitated the use of equivalent medicines, the company offers a diverse range of therapeutic drugs, including those for anti-infective, anti-neoplastic, cardiovascular, dermatological, gastrointestinal, neurological, ophthalmological, respiratory, and musculoskeletal conditions. In addition to pharmaceuticals, Doc Generici provides nutritional supplements and medical devices. The company emerged as a key player in the generic medicines market, particularly after distribution began in 2001 when regulations required pharmacists to offer lower-priced equivalent medications. As a subsidiary of Diocle S.p.A., Doc Generici is committed to maintaining high-quality standards while ensuring affordability for patients seeking effective treatment options.
Inscripta
Series C in 2019
Inscripta, Inc. is a gene editing technology company based in Boulder, Colorado, with additional offices in Pleasanton and San Diego, California. Founded in 2015, the company is focused on developing advanced CRISPR enzymes, specifically its proprietary MADzymes, to facilitate precision gene editing. Inscripta has created the first benchtop platform for scalable digital genome engineering, which includes an instrument, consumables, software, and assays that enable fully automated workflows for massively parallel editing of single cells. This innovative platform aims to empower scientists by overcoming existing technical and licensing challenges in gene editing research. By providing tools that allow for the generation of extensive libraries of designer proteins and genome variants, Inscripta supports researchers in designing, engineering, and evaluating genetic modifications with unprecedented ease and efficiency.
Omnipharm
Acquisition in 2019
Omnipharm, is a supplier of natural ingredients made in France
Inscripta
Series C in 2018
Inscripta, Inc. is a gene editing technology company based in Boulder, Colorado, with additional offices in Pleasanton and San Diego, California. Founded in 2015, the company is focused on developing advanced CRISPR enzymes, specifically its proprietary MADzymes, to facilitate precision gene editing. Inscripta has created the first benchtop platform for scalable digital genome engineering, which includes an instrument, consumables, software, and assays that enable fully automated workflows for massively parallel editing of single cells. This innovative platform aims to empower scientists by overcoming existing technical and licensing challenges in gene editing research. By providing tools that allow for the generation of extensive libraries of designer proteins and genome variants, Inscripta supports researchers in designing, engineering, and evaluating genetic modifications with unprecedented ease and efficiency.
Biobest
Private Equity Round in 2018
Biobest N.V. develops and supplies natural crop care systems. It specializes in bumblebee pollination and sustainable crop management. The company offers biological pollination products, such as bumblebees; biological control products, which include beneficial insects and mites, beneficial nematodes, and biopesticides; and monitoring and scouting products, including sticky traps and rolls, pheromone traps, and pheromone lures and attractants to growers.
Xeris Biopharma
Series C in 2018
Xeris Biopharma is a specialty pharmaceutical company focused on developing and commercializing innovative therapies for patient populations in endocrinology, neurology, and gastroenterology. The company utilizes its proprietary formulation technologies, XeriSol and XeriJect, to create ready-to-use, liquid-stable injectables that can deliver highly concentrated, non-aqueous formulations of peptides, proteins, antibodies, and small molecules. These technologies facilitate subcutaneous and intramuscular delivery, offering distinct advantages over traditional formulations, such as eliminating the need for reconstitution and enabling long-term room temperature stability. Xeris currently markets three products: Gvoke, a ready-to-use liquid glucagon for severe hypoglycemia; Keveyis, the first FDA-approved treatment for primary periodic paralysis; and Recorlev, approved for endogenous hypercortisolemia in Cushing's Syndrome. Additionally, the company has an extensive pipeline of development programs aimed at expanding its product offerings through its advanced formulation science.
Inscripta
Series C in 2018
Inscripta, Inc. is a gene editing technology company based in Boulder, Colorado, with additional offices in Pleasanton and San Diego, California. Founded in 2015, the company is focused on developing advanced CRISPR enzymes, specifically its proprietary MADzymes, to facilitate precision gene editing. Inscripta has created the first benchtop platform for scalable digital genome engineering, which includes an instrument, consumables, software, and assays that enable fully automated workflows for massively parallel editing of single cells. This innovative platform aims to empower scientists by overcoming existing technical and licensing challenges in gene editing research. By providing tools that allow for the generation of extensive libraries of designer proteins and genome variants, Inscripta supports researchers in designing, engineering, and evaluating genetic modifications with unprecedented ease and efficiency.
Stiplastics S.A.S.
Venture Round in 2018
Stiplastics S.A.S. engages in designing, developing, and manufacturing medical devices for the healthcare industry
Laboratoires Ineldea
Venture Round in 2017
Laboratoires Ineldea, based in Carros, France, specializes in the formulation, development, manufacturing, and marketing of a wide range of products, including nutritional supplements, health foods, organic cosmetics, and nutraceutical solutions. Established in 2003 by a team with over 20 years of experience in natural products, the company leverages recognized technical and scientific expertise to deliver innovative health solutions. With a diverse product portfolio exceeding 400 references, Laboratoires Ineldea is committed to quality and consistency, earning the trust of healthcare professionals and consumers alike. The company's products are marketed through pharmacies, drugstores, specialty stores, and health professionals across international markets, focusing on meeting the unique health needs of individuals at various life stages.
PhysioAssist
Series B in 2017
PhysioAssist, founded in 2012, is a company focused on developing medical devices aimed at treating obstructive respiratory diseases. By integrating expertise in the physics of materials, signal processing, and life sciences, PhysioAssist has created innovative solutions that enhance the quality of life for patients. Their patented technology modifies the physical properties of mucus, facilitating the mobilization and removal of secretions, which allows healthcare professionals to provide effective treatment for bronchial congestion. The design and ergonomics of their devices have been meticulously optimized for daily use in patient care, ensuring they meet the practical needs of both patients and healthcare providers.
Xeris Biopharma
Series C in 2017
Xeris Biopharma is a specialty pharmaceutical company focused on developing and commercializing innovative therapies for patient populations in endocrinology, neurology, and gastroenterology. The company utilizes its proprietary formulation technologies, XeriSol and XeriJect, to create ready-to-use, liquid-stable injectables that can deliver highly concentrated, non-aqueous formulations of peptides, proteins, antibodies, and small molecules. These technologies facilitate subcutaneous and intramuscular delivery, offering distinct advantages over traditional formulations, such as eliminating the need for reconstitution and enabling long-term room temperature stability. Xeris currently markets three products: Gvoke, a ready-to-use liquid glucagon for severe hypoglycemia; Keveyis, the first FDA-approved treatment for primary periodic paralysis; and Recorlev, approved for endogenous hypercortisolemia in Cushing's Syndrome. Additionally, the company has an extensive pipeline of development programs aimed at expanding its product offerings through its advanced formulation science.
Ivantis
Series C in 2017
Ivantis Inc. is a medical device company based in Irvine, California, focused on developing innovative treatments for primary open-angle glaucoma. Founded in 2007, the company specializes in a minimally invasive intracanalicular scaffold that alleviates high intraocular pressure by restoring the natural outflow pathway in Schlemm's canal. This device aims to provide a less invasive and more effective solution for the over 60 million individuals worldwide affected by this condition. In addition to its primary focus on glaucoma, Ivantis intends to explore innovative treatments for other ophthalmic diseases as it expands its product offerings. The company also provides a Session Persistence Server to support clinical trials, ensuring data protection for telnet task workers and terminal emulation users across various devices and operating systems.
LNA Sante
Post in 2016
LNA Sante is a global health player with nearly 70 establishments in France and Belgium. Nursing homes (EHPAD and MRS), Follow-up care and rehabilitation (SSR), Home hospitalization structures (HAD), Health centers, Psychiatric clinic. Our mission is to improve the quality of life for people who are temporarily or permanently vulnerable, in a welcoming and caring environment, suitable for everyone and for all ages. Our commitment "To care and take care" of you or your loved ones daily, patients and residents who are welcomed in our structures in France or in Belgium. A mission and commitment shared by all our teams.
Seqens
Private Equity Round in 2016
Seqens is a integrated in pharmaceutical synthesis and specialty ingredients, delivering unrivalled market responsiveness and tailor-made solutions to our customers.
Twist Bioscience
Series D in 2016
Twist Bioscience Corporation is a synthetic biology company based in South San Francisco, California, established in 2013. The company specializes in the production of synthetic DNA through its innovative DNA synthesis platform, which utilizes a proprietary semiconductor-based process on silicon chips. This approach allows for the rapid and cost-effective manufacturing of high-quality synthetic DNA, enabling applications in various fields, including healthcare, agriculture, industrial chemicals, and data storage. Twist Bioscience offers a range of products, including synthetic genes, tools for sample preparation, antibody libraries for drug discovery, and DNA for digital data storage. The company aims to empower customers in their quest for solutions that improve lives and sustainability, positioning itself as a key player in accelerating advancements in synthetic biology.
Origene
Venture Round in 2015
OriGene Technologies, Inc. is a biotechnology company based in Rockville, Maryland, specializing in the development, manufacturing, and sale of genome-wide research and diagnostic products. Established in 1995, OriGene offers a comprehensive array of tools for academic, diagnostic, pharmaceutical, and biotech applications. Its product portfolio includes cDNA clones, shRNA and siRNA reagents, CRISPR/Cas9 genome editing tools, proteins, antibodies, and anatomic pathology products. Additionally, the company provides services such as gene synthesis, custom cloning, and assay development, supporting a variety of research areas including cancer biomarker research and stem cell research. OriGene's extensive resources aim to facilitate gene-based research, enabling researchers to validate antibodies and develop new drugs. The company's products are distributed globally through various channels, including online platforms.
keepMED
Series B in 2015
keepMED Ltd. is a company focused on developing and commercializing innovative solutions for the treatment of Obstructive Sleep Apnea (OSA), a condition marked by repeated episodes of upper airway obstruction during sleep. The company's primary product, keePAP, is a lightweight and unobtrusive wearable device that includes a nasal interface and a miniature battery-operated control unit. Founded in 2012 and based in Rishon Le Zion, Israel, keepMED aims to provide effective treatment options for individuals suffering from OSA.
Ceva Santé Animale
Venture Round in 2014
Ceva Santé Animale S.A. specializes in the research, development, production, and marketing of veterinary pharmaceuticals and vaccines for both companion and farm animals. The company provides a diverse range of products, including treatments for behavior, cardiology, nephrology, dermatology, locomotion, parasitology, and reproduction management for companion animals. For farm animals, Ceva offers anti-infective products, vaccines, and reproductive management solutions for cattle, sheep, goats, swine, and poultry. Additionally, the company has developed tools such as the Ceva Lung Program, a mobile application that helps manage lung health in livestock. Established in 1988 and headquartered in Libourne, France, Ceva operates pharmaceutical and research facilities in various countries, including Canada, Brazil, Italy, Hungary, the United States, Japan, Mexico, China, and Canada. The company is actively involved in global welfare initiatives, collaborating with local organizations to enhance animal health and welfare.
ImaginAb
Series B in 2014
ImaginAb, Inc. is a clinical stage biotechnology company specializing in immune oncology imaging and radiopharmaceutical therapy. Founded in 2007 and headquartered in Inglewood, California, the company develops targeted imaging agents using its proprietary minibody and cys-diabody platforms. Its lead product, the 89Zr crefmirlimab berdoxam (CD8 ImmunoPET™), is currently in Phase II clinical trials and has been licensed by various pharmaceutical and biotech companies for use in their immunotherapy clinical trials. ImaginAb's portfolio includes precision imaging products for different cancers, such as CD8 and CD4 for immune-oncology, as well as PSMA PET for prostate cancer. By providing actionable insights into patient selection and treatment progress, ImaginAb aims to enhance precision medicine in oncology.
Kalila Medical
Venture Round in 2014
Kalila Medical focuses on developing advanced catheter technologies for vascular and intracardiac access. The company specializes in a platform of steerable sheaths designed to enhance precision during catheter-based procedures, particularly for atrial fibrillation ablation. Its initial product line includes sheaths compatible with both 8Fr and 12Fr ablation catheters, offering improved torque and tip control essential for effective catheter delivery and lesion formation. Beyond atrial fibrillation, Kalila's technology has applications in various endovascular procedures, including mitral valve repair, closure of atrial septal defects and patent foramen ovale, left atrial appendage closure, transseptal puncture, and left ventricular lead placement. Founded in 2010, Kalila Medical emerged from Shifamed LLC, a medical device incubator based in Silicon Valley.
Proclara Biosciences
Series D in 2014
Proclara Biosciences, Inc. is a biotechnology company focused on developing therapies for chronic neurodegenerative diseases and conditions associated with protein misfolding, such as Alzheimer’s and Parkinson’s diseases, as well as various orphan indications. Founded in 2006 and headquartered in Cambridge, Massachusetts, the company utilizes a protein disaggregation platform to create disease-modifying drug candidates. One of its notable candidates, NPT001, aims to disaggregate existing amyloid plaques associated with Alzheimer’s in preclinical models. Proclara's approach targets multiple misfolded proteins, positioning the company to potentially transform treatment outcomes for patients suffering from these challenging diseases.
Lavorel Medicare
Venture Round in 2013
Lavorel Medicare is a service provider specialized in nursing care at home or in special care units. Its German subsidiary Bonitas GmbH, which employs about 3,000 people, specializes in medical support to disabled patients with chronic diseases or genetic pathologies .Bonitas GmbH supports over 2,000 patients throughout the German territory, through 50 agencies.
HumanCharger
Series A in 2013
HumanCharger is a developer of innovative light therapy devices that utilize a patented mechanism to enhance mental performance and well-being. By delivering calibrated white light through the ear canals, the device stimulates photosensitive proteins in the brain. This unique approach allows users to experience benefits such as increased energy levels, improved mood, heightened mental alertness, and reduced symptoms of seasonal affective disorder. The device is designed to be portable, making it convenient for daily use, with just 12 minutes of application recommended to achieve significant positive effects.
Lavorel Medicare
Private Equity Round in 2013
Lavorel Medicare is a service provider specialized in nursing care at home or in special care units. Its German subsidiary Bonitas GmbH, which employs about 3,000 people, specializes in medical support to disabled patients with chronic diseases or genetic pathologies .Bonitas GmbH supports over 2,000 patients throughout the German territory, through 50 agencies.
Proclara Biosciences
Series C in 2013
Proclara Biosciences, Inc. is a biotechnology company focused on developing therapies for chronic neurodegenerative diseases and conditions associated with protein misfolding, such as Alzheimer’s and Parkinson’s diseases, as well as various orphan indications. Founded in 2006 and headquartered in Cambridge, Massachusetts, the company utilizes a protein disaggregation platform to create disease-modifying drug candidates. One of its notable candidates, NPT001, aims to disaggregate existing amyloid plaques associated with Alzheimer’s in preclinical models. Proclara's approach targets multiple misfolded proteins, positioning the company to potentially transform treatment outcomes for patients suffering from these challenging diseases.
Biom'Up
Series B in 2012
Biom'Up, expert in the field of resorbable biomaterials, designs, develops and manufactures unique medical devices based on collagen technology. These innovative and clinically proven products cover many different surgical specialties - orthopaedics, spinal, cardiac, general and maxillo-facial - and improve patient healing by allowing guided regeneration of soft tissues and bone.
Advencis
Private Equity Round in 2012
Advencis is a developer and manufacturer of lab instruments and medical devices.The company has developed Advencis Bio-System Incubator, a modular system of early detection which is fully automated for industrial microbiology (food and pharmaceutical industries) and clinical markets. The system provides highly sensitive detection of the microorganisms on agar plates and on filter-based devices. It also provides Advencis Bio-System Software which is a real time monitoring application.
Proclara Biosciences
Series B in 2012
Proclara Biosciences, Inc. is a biotechnology company focused on developing therapies for chronic neurodegenerative diseases and conditions associated with protein misfolding, such as Alzheimer’s and Parkinson’s diseases, as well as various orphan indications. Founded in 2006 and headquartered in Cambridge, Massachusetts, the company utilizes a protein disaggregation platform to create disease-modifying drug candidates. One of its notable candidates, NPT001, aims to disaggregate existing amyloid plaques associated with Alzheimer’s in preclinical models. Proclara's approach targets multiple misfolded proteins, positioning the company to potentially transform treatment outcomes for patients suffering from these challenging diseases.
Amplitude
Series B in 2012
AMPLITUDE TECHNOLOGIES is the global expert in the science, design and manufacture of high performance laser systems for a variety of specialist applications. ln addition to systems used for fundamental physics research, the company is a leading authority in the medical research domain including radiography and cancer treatment projects. AMPLITUDE TECHNOLOGIES offers worldwide project management experience. Its comprehensive project management program provides industry-leading levels of customer support. From the first steps of the design concept, to laboratory installation, training and ongoing after-sales requirements, the Amplitude team is on-hand to provide the support the application demands. Over a decade' s experience in the Science, design and development, and support of state-of-the-art systems in the field means that every AMPLITUDE TECHNOLOGIES system is engineered to be extremely robust and reliable, offering unparalleled performance no matter what the application.
Proclara Biosciences
Series B in 2011
Proclara Biosciences, Inc. is a biotechnology company focused on developing therapies for chronic neurodegenerative diseases and conditions associated with protein misfolding, such as Alzheimer’s and Parkinson’s diseases, as well as various orphan indications. Founded in 2006 and headquartered in Cambridge, Massachusetts, the company utilizes a protein disaggregation platform to create disease-modifying drug candidates. One of its notable candidates, NPT001, aims to disaggregate existing amyloid plaques associated with Alzheimer’s in preclinical models. Proclara's approach targets multiple misfolded proteins, positioning the company to potentially transform treatment outcomes for patients suffering from these challenging diseases.
QuantaLife
Series B in 2010
QuantaLife, Inc. was formed to develop, manufacture and market a revolutionary nucleic acid testing concept for the Life Science Research, Clinical Molecular Diagnostics, Personalized Medical Care and Industrial markets. Our suite of products, which are based on our proprietary nucleic acid testing method, will enable rapid detection and quantification of nucleic acids in complex samples on a flexible, automated instrument. This technology provides an order of magnitude improvement in performance over current platforms at a fraction of the cost. QuantaLife is a small biotechnology startup involved in the early development phases of the technology.
SuperSonic Imagine
Series C in 2010
SuperSonic Imagine SA is a medical technology company that specializes in developing and manufacturing advanced ultrasound imaging systems. Founded in 2005 and headquartered in Aix-en-Provence, France, the company is renowned for its Aixplorer system, which provides high-definition imaging and is particularly effective in diagnosing and monitoring breast, prostate, and thyroid cancers, as well as liver diseases. The Aixplorer system incorporates ShearWave technology, enabling quantitative elastography that measures tissue elasticity. SuperSonic Imagine operates primarily in markets such as China, the United States, and various European countries, distributing its products through a network of offices and distributors. As a subsidiary of Hologic Hub Ltd, the company continues to innovate in the field of medical imaging, enhancing the capabilities of healthcare professionals.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.